Clinical Trial Update: Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating elesclomol sodium with paclitaxel in patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Fallopian Tube Clear Cell Adenocarcinoma
• Fallopian Tube Endometrioid Adenocarcinoma
• Fallopian Tube Mucinous Adenocarcinoma
• Fallopian Tube Serous Adenocarcinoma
• Fallopian Tube Transitional Cell Carcinoma
• Fallopian Tube Undifferentiated Carcinoma
• Ovarian Brenner Tumor
• Ovarian Carcinoma
• Ovarian Clear Cell Adenocarcinoma
• Ovarian Endometrioid Adenocarcinoma
• Ovarian Mucinous Adenocarcinoma
• Ovarian Seromucinous Carcinoma
• Ovarian Serous Adenocarcinoma
• Ovarian Transitional Cell Tumor
• Ovarian Undifferentiated Carcinoma
• Peritoneal Carcinoma
• Peritoneal Serous Adenocarcinoma

Drugs mentioned

• Elesclomol Sodium with Paclitaxel (elesclomol sodium + paclitaxel)

Snippet

Sponsor: GOG Foundation | Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-09-17